Related Experiment Video
Updated: May 1, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
The high mobility group A1 molecular switch: turning on cancer - can we turn it off?
1The Johns Hopkins University School of Medicine, Hematology Division , Ross Research Building, Room 1015, 720 Rutland Avenue, Baltimore MD 21205 , USA.
Introduction:
Emerging evidence demonstrates that the high mobility group A1 (HMGA1) chromatin remodeling protein is a key molecular switch required by cancer cells for tumor progression and a poorly differentiated, stem-like state. Because the HMGA1 gene and proteins are expressed at high levels in all aggressive tumors studied to date, research is needed to determine how to 'turn off' this master regulatory switch in cancer.
Areas Covered:
In this review, we describe prior studies that underscore the central role of HMGA1 in refractory cancers and we discuss approaches to target HMGA1 in cancer therapy.
Expert Opinion:
Given the widespread overexpression of HMGA1 in diverse, aggressive tumors, further research to develop technology to target HMGA1 holds immense promise as potent anticancer therapy. Previous work in preclinical models indicates that delivery of short hairpin RNA or interfering RNA molecules to 'switch off' HMGA1 expression dramatically impairs cancer cell growth and tumor progression. The advent of nanoparticle technology to systemically deliver DNA or RNA molecules to tumors brings this approach even closer to clinical applications, although further efforts are needed to translate these advances into therapies for cancer patients.
Insights
High mobility group A1 (HMGA1) is crucial for aggressive cancers. Targeting HMGA1 with RNA interference, potentially via nanoparticles, shows promise for novel cancer therapies by inhibiting tumor progression.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- High mobility group A1 (HMGA1) acts as a critical regulator in cancer progression.
- HMGA1 overexpression is prevalent in aggressive tumors, driving a stem-like, undifferentiated state.
Purpose of the Study:
- To review the role of HMGA1 in refractory cancers.
- To discuss therapeutic strategies targeting HMGA1 for cancer treatment.
Main Methods:
- Review of existing preclinical studies on HMGA1.
- Exploration of RNA interference (RNAi) approaches to silence HMGA1.
- Discussion of nanoparticle-mediated delivery systems for RNAi.
Main Results:
- HMGA1 is a key driver of tumor progression and dedifferentiation.
- Preclinical models demonstrate that inhibiting HMGA1 expression significantly impairs cancer growth.
- Nanoparticle technology offers a viable route for systemic delivery of HMGA1-targeting agents.
Conclusions:
- Targeting HMGA1 presents a promising therapeutic strategy for diverse aggressive cancers.
- RNA interference offers a method to "switch off" HMGA1, hindering cancer progression.
- Advancements in nanoparticle delivery are advancing the clinical translation of HMGA1-targeted therapies.
Related Concept Videos
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:53Adaptive Mechanisms in Cancer Cells